Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

Wed, 13th Mar 2024 20:49

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

PensionBee Group PLC - UK online pension provider - Says revenue increased 35% to GBP23.8 million in 2023 from GBP17.7 million a year prior. Pretax loss narrowed to GBP10.7 million from GBP22.4 million. Adjusted loss before interest, tax, depreciation and amortisation shrunk to GBP8.2 million from GBP19.5 million. Basic loss per share dropped 53% to 4.73p from 9.97p. Assets under administration reached GBP4.35 billion at year-end, up 44% from GBP3.03 billion at the end of 2022. Chief Executive Officer Romi Savova says: "Having met our longstanding and ambitious goal of achieving adjusted Ebitda profitability across the fourth quarter of 2023, we are confident in our continued growth, underpinned by profitability...we have announced our proposed expansion into the US, the world's largest defined contribution pension market, where we see an enormous opportunity to assist many consumers in the US who also struggle to prepare adequately for retirement as they navigate a complex and confusing pensions landscape." Looking ahead, PensionBee says it is aiming to onboard 1 million invested customers, creating a revenue ambition of around GBP150 million in the long term.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based drug discovery and development company - Says its pretax loss widened to EUR30.9 million in 2023 from EUR28.7 million a year prior. The company's net assets totalled a negative EUR15.2 million at year-end, increased from a negative EUR11.5 million at the end of 2022. Says trials of its Bexmarilab cancer immunotherapy candidate made significant progress over the year. Chief Executive Officer Markku Jalkanen says: "Throughout the course of the year, we have reported highly encouraging data for bexmarilimab, showing a remarkable overall response rate in both higher-risk frontline MDS patients as well as HMA-failed MDS patients. These are highly significant findings, given the combinations of treatments these patients had previously failed on and the very limited options available for future therapy. They provide us with a path to market and only bolster our confidence in the potential of this novel immunotherapy to treat patients with aggressive hematological malignancies."

----------

Public Policy Holdings Company Inc - Washington DC-based group of advisory firms specialising in government addairs and public relations - Achieves "record financial performance and excellent strategic progress" in 2023. Revenue grew 24% to USD135.0 million from USD108.8 million. Underlying Ebitda rose 12% to USD35.1 million from USD31.2 million, in line with market expectations. Underlying net income increased 14% to USD26.5 million from USD23.3 million. Basic underlying earnings per share rose 9.7% to 23.54 cents from 21.45 cents. PPHC's annual dividend of 14.30 cents per share was 2.1% ahead of 14.00 cents a year before. All business segments achieved year-on-year growth. The company credits its successful year to several acquisitions, including MultiState Associates Inc, which "contribut[ed] healthily to group revenue and Ebitda" over 2023. PPHC continues to target an Ebitda margin of between 25% and 30%, in line with 2023's 26% margin. Chief Executive Officer Stewart Hall says: "The increasing demand for our services has enabled us to generate solid levels of organic growth and healthy expansion in total client numbers. Strategically, we are progressing well with a healthy pipeline of value accretive acquisition opportunities and the strength of our holding company model being validated by the outperformance of our two most recent acquisitions."

----------

Sovereign Metals Ltd - Graphite development company focused on projects in Malawi - In the half-year ended December 31, the company's operating loss was AUD7.0 million, narrowed from AUD8.5 million a year prior. Exploration and evaluation expenditure totalled AUD5.0 million, down from AUD5.8 million, which the company says stems from the pre-feasibility study at its Kasiya project in Malawi. Interest income grew to AUD938,402 from AUD138,366.

----------

Commonwealth Bank of Australia - Sydney-based financial services company and retail bank - Issues subordinated notes worth USD1.25 billion, due March 2034. The notes were issued pursuant to the company's USD50.00 billion senior and subordinated medium term notes program.

----------

OptiBiotix Health Ltd - life sciences company focused on tackling obesity, high cholesterol, diabetes and skincare - Signs partnership agreement with Dr Morepen Ltd, a New Delhi-based diagnostics company, for the sale of SlimBiome weight-loss products in India under the latter's brand. Chief Executive Officer Stephen O'Hara says: "Morepen brings an extensive sales team with experience of highly differentiated scientific products and countrywide access to a network of around 500,000 pharmacies across India. Based on current forecasts, the directors anticipate this agreement could contribute in the region of GBP6-7 million revenue per annum in the next four to five years."

----------

MacFarlane Group PLC - Glasgow-based packaging company - Acquires Allpack Packaging Supplies Ltd, a Bury Saint Edmunds-based packing materials business. Says the "earnings-enhancing acquisition further progresses Macfarlane's strategy to build its protective packaging business through a combination of organic and acquisitive growth". In 2023, Allpack delievered GBP3.0 million in sales alongside Ebitda and pretax profits of GBP600,000. All of Allpack's employees will join MacFarlane. MacFarland will provide a maximum consideration of GBP3.3 million, including a GBP750,000 performance-based earn-out, financed from the company's existing bank facility.

----------

Cora Gold Ltd - gold exploration company focused on Mali and Senegal - Following conversion of USD2.3 million of convertible loan notes for 82.0 million ordinary shares of no par value in the company, has issued an outstanding CLN for a total of USD13.0 million matured on March 12. The company's cash balance is now in excess of USD2.9 million. Chief Executive Officer Bert Monro says: "With strong cash reserves, we look forward to providing progress updates on our Sanankoro gold project in Mali, including submission of the application for a mining permit once the current moratorium is lifted, as well as wider exploration activities across our permits."

----------

Electric Guitar PLC - Reading-based marketing services company - Intends to request the Financial Conduct Authority to cancel the company's shares on the FCA official list and cease admission to trading on the main market of the London Stock Exchange. This is ahead of its proposed application for admission of its shares to trading on AIM. The company expects to convene a shareholder meeting to approve its acquisition of 3radical Ltd in the coming weeks.

----------

Capricorn Energy PLC - Edinburgh-based oil and gas exploration company - Securities and Exchange Board of India has ordered Vedanta Ltd to pay the company USD9.5 million within 45 days. The payment related to a non-payment of a dividend to Capricorn UK Holdings by Vedanta, a Mumbai-based mining company.

----------

Oxford BioDynamics PLC - Oxford-based biotechnology company with a portfolio of clinical tests using its EpiSwitch technology - Announces a fundraising by way of a placing to raise GBP9 million and a retail offer for up to GBP1.3 million, both with an issue price of 9p per share. The issue price represents a 21% discount to the company's closing price of 11.40p on Tuesday. The results of the placing are expects to be released on Thursday. Shares in Oxford BioDynamics closed down 11% at 10.20 pence each in London on Wednesday.

----------

Cooks Coffee Co Ltd - New Zealand-based UK-focused cafe chain - Announces its intention to undertake a placement and share purchase plan. The scheme will result in up to 5.7 million new shares in the company at an issue price of NZD0.20 per share, targeting a raise of up to NZD1.7 million, roughly GBP820,000. Cooks says that the purpose of the fundraise is to invest in improvements in the company's digital programs, including its delivery, click and collect, loyalty programs, as well as expanding its businesses in the Middle East and Europe.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
13 Mar 2024 11:52

Faron Pharmaceuticals reports year of clinical progress

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously hypomethylating agent (HMA)-failed and higher-risk myelodysplastic syndrome (MDS) patient populations in the phase one part of the BEXMAB study.

Read more
6 Mar 2024 16:06

UK earnings, trading statements calendar - next 7 days

Thursday 7 March 
Admiral Group PLCFull Year Results
Aviva PLCFull Year Results
Beazley PLCFull Year Results
Brooks Macdonald Group PLCHalf Year Results
Coats Group PLCFull Year Results
Darktrace PLCHalf Year Results
Elementis PLCFull Year Results
Entain PLCFull Year Results
Funding Circle Holdings PLCFull Year Results
Harbour Energy PLCFull Year Results
ITV PLCFull Year Results
Kier Group PLCFull Year Results
Melrose Industries PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
PageGroup PLCFull Year Results
Physiomics PLCHalf Year Results
Rentokil Initial PLCFull Year Results
Robert Walters PLCFull Year Results
Spirax-Sarco Engineering PLCFull Year Results
TT Electronics PLCFull Year Results
Tyman PLCFull Year Results
Friday 8 March 
Informa PLCFull Year Results
Just Group PLCFull Year Results
LMS Capital PLCFull Year Results
Stelrad Group PLCFull Year Results
Monday 11 March 
HgCapital Trust PLCFull Year Results
Mincon Group PLCFull Year Results
MTI Wireless Edge LtdFull Year Results
Tuesday 12 March 
BATM Advanced Communications LtdFull Year Results
Costain Group PLCFull Year Results
Domino's Pizza Group PLCFull Year Results
Fonix Mobile PLCHalf Year Results
Foresight Solar Fund LtdFull Year Results
Genuit PLCFull Year Results
H&T Group PLCFull Year Results
Hill & Smith PLCFull Year Results
MaxCyte IncFull Year Results
Persimmon PLCFull Year Results
Synthomer PLCFull Year Results
Target Healthcare REIT PLCHalf Year Results
TI Fluid Systems PLCFull Year Results
TP ICAP Group PLCFull Year Results
Wednesday 13 March 
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Balfour Beatty PLCFull Year Results
Centaur Media PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Ferrexpo PLCFull Year Results
Gym Group PLCFull Year Results
Hochschild Mining PLCFull Year Results
IP Group PLCFull Year Results
Keywords Studios PLCFull Year Results
Kin & Carta PLCHalf Year Results
Metro Bank Holdings PLCFull Year Results
Nexteq PLCFull Year Results
PensionBee Group PLCFull Year Results
Public Policy Holding Co IncFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Supermarket Income REIT PLCHalf Year Results
Trainline PLCTrading Statement
Vaalco Energy IncFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.

Read more
4 Mar 2024 19:59

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
4 Mar 2024 10:40

Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans

(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.

Read more
27 Feb 2024 21:12

TRADING UPDATES: Armadale Capital eyes Mahenge project financing

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
22 Feb 2024 14:26

UK earnings, trading statements calendar - next 7 days

Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Harmony Energy Income Trust PLCFull Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
Thursday 29 February 
Cairn Homes PLCFull Year Results
CVS Group PLCFull Year Results
Drax Group PLCFull Year Results
Faron Pharmaceuticals LtdFull Year Results
Haleon PLCFull Year Results
Hammerson PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Hunting PLCFull Year Results
International Biotechnology Trust PLCFull Year Results
London Stock Exchange Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Man Group PLCFull Year Results
Mobico Group PLCFull Year Results
Nexus Infrastructure PLCFull Year Results
Ocado Group PLCFull Year Results
PPHE Hotel Group LtdFull Year Results
Schroder Oriental Income Fund LtdFull Year Results
Schroders PLCFull Year Results
Serco Group PLCFull Year Results
Shaftesbury Capital PLCFull Year Results
Spectris PLCFull Year Results
Spire Healthcare Group PLCFull Year Results
Vesuvius PLCFull Year Results
Weir Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
19 Feb 2024 11:23

Faron discloses events of default on debt obligations to lender

(Alliance News) - Faron Pharmaceuticals Ltd shares fell on Monday, after it said it is in breach of several undertakings agreed in a secured debt deal with lender IPF Fund II SCA, SICAV-FIAR.

Read more
25 Jan 2024 20:09

TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
9 Jan 2024 12:36

Faron launches second phase of leukaemia treatment trial

(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.

Read more
9 Jan 2024 10:56

Faron says first patient dosed in phase two Bexmab trial for cancer

(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial.

Read more
11 Dec 2023 13:22

Faron unveils promising antibody study results

(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on Monday.

Read more
11 Dec 2023 12:01

Faron Pharmaceuticals hails positive results of cancer drug trial

(Alliance News) - Faron Pharmaceuticals Ltd on Monday said results from a probe of a cancer drug were promising.

Read more
7 Dec 2023 19:33

IN BRIEF: Faron Pharma celebrates publication of bexmarilimab results

Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilimab have been published in Cell Reports Medicine, an open-access journal. According to the trial, bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumours. It also showed that CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects, and that bexmarilimab induced macrophage activation and increased IFNy signalling in patients who achieved disease control and prolonged survival.

Read more
7 Dec 2023 11:01

Faron publishes cancer immunotherapy study findings

(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised monoclonal anti-CLEVER-1 antibody aimed at transforming the landscape of anticancer immunotherapies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.